Extensive Phase II Data Of Amprenavir (141W94/VX-478) To Be Presented

Amprenavir's emerging profile is of a highly potent drug, well-tolerated in two-, three-, and four-drug combinations. Among the data being reported that support this view, we direct you to the following key presentations:

  • First results of amprenavir used in double protease inhibitor (PI) combinations. Preliminary dual PI combination data shows high potency and a rapid antiviral effect (80% of patients with undetectable virus at 4 weeks), with good tolerability, in patients who have previously taken reverse transcriptase inhibitors. We expect 16-week data will be presented, showing a sustained antiviral effect as measured by the percentage of patients with undetectable virus. Data will be presented at the conference by Dr. Joseph Eron from University of North Carolina on Monday, February 2 at 10:30AM.
  • Extended results of amprenavir in combination with 1592, an experimental reverse transcriptase inhibitor. This two-drug, twice daily combination showed a rapid and potent antiviral effect (13 of 17 patients evaluated had undetectable virus at 4 weeks, and 12 of 12 evaluated at 8 weeks had undetectable virus). We expect that 16 week-data will be presented, documenting a sustained antiviral effect. The author of this poster exhibit, which will be presented on Tuesday, February 3, is Dr. Pierre Bart of Lausanne, Switzerland.

A second study being presented describes 1592/amprenavir therapy in the context of other 1592/PI treatment possibilities. Available four week data confirms the rapid and potent antiviral effect of 1592 and amprenavir. Longer term data that demonstrates amprenavir's potency compared with other 1592/PI regimens will be the subject of an oral presentation given by Dr. John Mellors of the University of Pittsburgh Medical Center on Monday, February 2, at 10:30AM. Amprenavir is currently being evaluated in pivotal Phase III clinical trials with development partner Glaxo Wellcome. A U.S. new drug application (NDA)

Contact: Justine Schultz
(617) 577-6619
Vertex Pharmaceuticals

Page: 1 2

Related biology news :

1. Extensive research survey confirms life on Earth now being affected by global warming
2. PSA Levels Mean More Extensive Prostate Disease In Older Men
3. Phase II trials of second-generation antisense cancer drug planned following successful early study
4. OneWorld Health completes enrollment, treatment in Phase III India trial
5. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
6. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. KEPPRA international Phase IV SKATE study results show favourable efficacy
9. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
10. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
11. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: